epithelioid hemangioendothelioma ehe rare tumor first characterized sharon weiss franz enzinger clinically histologically intermediate angiosarcoma hemangioma however distinct diseasedefining genetic alteration recently described ehe indicates entirely separate entity angiosarcoma hemangioma ehe soft tissue sarcoma generally considered vascular cancer insofar lesional cells surface markers typical endothelial cells cells lining interior blood vessels ehe originally described occurring commonly veins extremities arms legs two organs lungs since described organs throughout body addition liver lungs bones skin frequent organs initial description weiss tumor reported variety names including histiocytoid hemangioendothelioma intravascular bronchoalveolar tumor lung sclerosing cholangiocarcinoma lung liver common sites metastatic tumor likely confused carcinoma far common type tumor ehe typically occurs age range although overall age range involved much broader modest predilection females males often indolent course many affected people survived decades multiorgan extent number organs involved apparently little effect longevity cytogenetics ehe gave first clues underlying genetic alteration balanced reciprocal translocation ehe tumor cells first described mendlick et al led landmark paper tanas et al describing specific genes involved translocation associated common forms ehe alteration results fusion genes coding two transcription coactivators transcriptional regulators taz transcriptional coactivator pdzbinding motif also known ww domaincontaining transcription regulator protein calmodulinbinding transcription activator names parentheses relevant casual even science readers included help distinguish genes instance another gene entirely different function tafazzin unrelated ehe confusingly also referred taz case ehe translocation results abnormal fusion gene expresses abnormal mrna resulting synthesis fusion protein variant taz always turned form taz always resides nucleus therefore constitutively active binds turns important member tead family transcription factors causes cells proliferate production taztead transcriptome causes affected endothelial cells grow tumors normal cells taz considered major negative transducer hippo pathway signaling system regulates organ size causing cells stop growing touch contact inhibition many upstream inputs regulate hippo signal normally functions turn deactivate taz keeping cytoplasm nucleus ehe cells abnormal fusion taz immune input stays nucleus continuing stimulate cell growth note ehe patients harbor different translocation one similarly results constitutive activation yap orthologue taz ie gene sequence function similar taz also results persistent unregulated growth affected cells therefore causes ehetype tumors although epithelioid hemangioendothelioma typically presents lowgrade tumor occasionally ehae presents high grade aggressive ehae presenting pleura example associated much aggressive hard treat standard chemotherapy treatment ehae current success drugs interferon paclitaxel maid combination chemotherapy thalidomide doxorubicin reported rare percent cancer population affects person every around cases diagnosed united states every unresponsive known strain chemotherapy making treatment difficult facebook site set people also registry patients enter medical cravat center research analysis vascular tumors website ehe ehe rare cancer foundation australia established australians epithelioid hemangioendothelioma core objective ehe rare cancer foundation australia proactively fundraise order support research rare cancer hope maintenance program cure photographer actress kris carr diagnosed stable low grade version ehae carr become success wellness warrior advocating vegan lifestyle way avoid stabilize httpsenwikipediaorgwikiepithelioidhemangioendothelioma